Suppr超能文献

缩小无菌生产差距以提高患者安全 - 第2部分。实施

Increasing Patient Safety by Closing the Sterile Production Gap-Part 2. Implementation.

作者信息

Agalloco James P

机构信息

Agalloco & Associates Inc., 22 Carriage Trail, Belle Mead, NJ 08502

出版信息

PDA J Pharm Sci Technol. 2017 Jul-Aug;71(4):269-273. doi: 10.5731/pdajpst.2016.007112. Epub 2017 Jan 15.

Abstract

Terminal sterilization is considered the preferred means for the production of sterile drug products because it affords enhanced safety for the patient as the formulation is filled into its final container, sealed, and sterilized. Despite the obvious patient benefits, the use of terminal sterilization is artificially constrained by unreasonable expectations for the minimum time-temperature process to be used. The core misunderstanding with terminal sterilization is a fixation that destruction of a high concentration of a resistant biological indicator is required. The origin of this misconception is unclear, but it has resulted in sterilization conditions that are extremely harsh (15 min at 121 °C, of F >8 min), which limit the use of terminal sterilization to extremely heat-stable formulations. These articles outline the artificial nature of the process constraints and describe a scientifically sound means to expand the use of terminal sterilization by identifying the correct process goal-the destruction of the bioburden present in the container prior to sterilization. Recognition that the true intention is bioburden destruction in routine products allows for the use of reduced conditions (lower temperatures, shorter process dwell, or both) without added patient risk. By focusing attention on the correct process target, lower time-temperature conditions can be used to expand the use of terminal sterilization to products unable to withstand the harsh conditions that have been mistakenly applied. The first article provides the background, and describes the benefits to patient, producer, and regulator. The second article includes validation and operational advice that can be used in the implementation. Terminal sterilization is considered the preferred means for the production of sterile drug products because it affords enhanced safety for the patient as the formulation is filled into its final container, sealed, and sterilized. Despite the obvious patient benefits, the use of terminal sterilization is artificially constrained by unreasonable expectations for the minimum time-temperature process to be used. These articles outline the artificial nature of the process constraints and describe a scientifically sound means to expand the use of terminal sterilization by identifying the correct process goal-the destruction of the bioburden present in the container prior to sterilization. By focusing attention on the correct process target, lower time-temperature conditions can be used to expand the use of terminal sterilization to products unable to withstand the harsh conditions that have been mistakenly applied. The first article provides the background, and describes the benefits to patient, producer, and regulator. The article manuscript includes validation and operational advice that can be used in the implementation.

摘要

最终灭菌被认为是生产无菌药品的首选方法,因为在制剂灌装到最终容器、密封并灭菌时,它能为患者提供更高的安全性。尽管对患者有明显益处,但最终灭菌的使用却受到对所用最低时间 - 温度工艺不合理期望的人为限制。对最终灭菌的核心误解在于,人们固定地认为需要杀灭高浓度的抗性生物指示剂。这种误解的起源尚不清楚,但它导致了极其严苛的灭菌条件(121℃下15分钟,F值>8分钟),这使得最终灭菌仅限于极其耐热的制剂。这些文章概述了工艺限制的人为性质,并描述了一种科学合理的方法,即通过确定正确的工艺目标——在灭菌前杀灭容器中存在的生物负荷,来扩大最终灭菌的应用范围。认识到常规产品的真正目的是生物负荷的杀灭,就可以采用更低的条件(更低的温度、更短的工艺停留时间或两者兼而有之),而不会增加患者风险。通过将注意力集中在正确的工艺目标上,可以使用更低的时间 - 温度条件,将最终灭菌的应用范围扩大到无法承受错误应用的严苛条件的产品。第一篇文章提供了背景信息,并描述了对患者、生产商和监管机构的益处。第二篇文章包括可用于实施的验证和操作建议。最终灭菌被认为是生产无菌药品的首选方法,因为在制剂灌装到最终容器、密封并灭菌时,它能为患者提供更高的安全性。尽管对患者有明显益处,但最终灭菌的使用却受到对所用最低时间 - 温度工艺不合理期望的人为限制。这些文章概述了工艺限制的人为性质,并描述了一种科学合理的方法,即通过确定正确的工艺目标——在灭菌前杀灭容器中存在的生物负荷,来扩大最终灭菌的应用范围。通过将注意力集中在正确的工艺目标上,可以使用更低的时间 - 温度条件,将最终灭菌的应用范围扩大到无法承受错误应用的严苛条件的产品。第一篇文章提供了背景信息,并描述了对患者、生产商和监管机构的益处。文章手稿包括可用于实施的验证和操作建议。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验